Amgen Inc. (NASDAQ:AMGN) is included among the 13 NASDAQ Stocks with Highest Dividends.
On April 10, Morgan Stanley analyst Terence Flynn raised the firm’s price recommendation on Amgen Inc. (NASDAQ:AMGN) to $326 from $309. It reiterated an Equal Weight rating on the shares. The firm updated its models across biopharma coverage, reflecting IQVIA trends and intra-quarter changes ahead of Q1 earnings.
On April 8, Truist also boosted its price goal on Amgen to $325 from $319 and maintained a Hold rating. The update came as part of a broader preview of Q1 earnings across the biotech sector. The firm said that reactions to regulatory and policy shifts have started to ease. It also pointed to a recent pickup in deal activity, which it believes could carry momentum through the rest of the year and into the mid-term period. For Amgen specifically, Truist raised its longer-term penetration assumptions for Krystexxa, reflecting stronger patent protection through 2040. It also increased the probability of success for MariTide, citing improved confidence in its commercial potential in obesity.
Amgen Inc. (NASDAQ:AMGN) is a biotechnology company focused on developing treatments for serious diseases. It works on discovering, developing, manufacturing, and delivering medicines, with a focus on areas of high unmet medical need. The company operates within the human therapeutics segment.
While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Blue Chip Stocks with Highest Dividends and 15 Best Cheap Dividend Stocks to Buy
Disclosure: None. Follow Insider Monkey on Google News.
